Fresenius SE Research and Development Expenses 2016-2024 | FSNUY

Fresenius SE annual/quarterly research and development expenses history and growth rate from 2016 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Fresenius SE research and development expenses for the quarter ending June 30, 2024 were $0.167B, a 23.84% decline year-over-year.
  • Fresenius SE research and development expenses for the twelve months ending June 30, 2024 were $0.602B, a 35.27% decline year-over-year.
  • Fresenius SE annual research and development expenses for 2023 were $0.715B, a 21.68% decline from 2022.
  • Fresenius SE annual research and development expenses for 2022 were $0.913B, a 4.09% decline from 2021.
  • Fresenius SE annual research and development expenses for 2021 were $0.952B, a 11.02% increase from 2020.
Fresenius SE Annual Research and Development Expenses
(Millions of US $)
2023 $715
2022 $913
2021 $952
2020 $858
2019 $722
2018 $795
2017 $631
2016 $553
2015 $515
Fresenius SE Quarterly Research and Development Expenses
(Millions of US $)
2024-06-30 $167
2024-03-31 $151
2023-12-31 $99
2023-09-30 $185
2023-06-30 $219
2023-03-31 $213
2022-12-31 $287
2022-09-30 $211
2022-06-30 $215
2022-03-31 $201
2021-12-31 $237
2021-09-30 $254
2021-06-30 $237
2021-03-31 $224
2020-12-31 $242
2020-09-30 $193
2020-06-30 $218
2020-03-31 $205
2019-12-31 $170
2019-09-30 $225
2019-06-30 $154
2019-03-31 $174
2018-12-31 $217
2018-09-30 $185
2018-06-30 $198
2018-03-31 $195
2017-12-31 $212
2017-09-30 $155
2017-06-30 $134
2017-03-31 $129
2016-12-31 $156
2016-09-30 $142
2016-06-30 $131
2016-03-31 $125
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $19.458B $24.011B
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $17.988B 18.23
DaVita (DVA) United States $12.872B 16.65
Encompass Health (EHC) United States $9.984B 23.54
Chemed (CHE) United States $8.238B 25.32
Elanco Animal Health (ELAN) United States $6.580B 15.66
RadNet (RDNT) United States $5.911B 130.90
Option Care Health (OPCH) United States $3.713B 17.60
Amedisys (AMED) United States $2.948B 20.98
LifeStance Health (LFST) United States $2.770B 0.00
Astrana Health (ASTH) United States $2.302B 31.49
Addus HomeCare (ADUS) United States $2.180B 25.57
U.S Physical Therapy (USPH) United States $1.368B 35.96
Aveanna Healthcare Holdings (AVAH) United States $1.121B 0.00
Pennant (PNTG) United States $1.093B 44.18
Atai Life Sciences (ATAI) Germany $0.290B 0.00
Daxor (DXR) United States $0.043B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.015B 0.00
Psychemedics (PMD) United States $0.014B 0.00
ATI Physical Therapy (ATIP) United States $0.008B 0.00
Ontrak (OTRK) United States $0.008B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00